Rocket One Inc.RKTO
Price (close)
$0.76
Market cap
$18.9M
P/E
—
Revenue (TTM)
—
Net income
-$13.3M
Dividend yield
—
1-year total return
-58.0%
Net margin
—
Revenue growth
—
Debt / equity
—
What Rocket One Inc. does.
focused on developing new generation therapies for unmet medical needs. We are focused on developing (i) a topical formulation for treating
side effects from drugs used for the treatment of cancer (HT-001); (ii) a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT);
and (iii) a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). We also have assets being
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$7.2M | -$14.3M | -$11.4M | -$8.1M | -$8.2M | -$12.5M |
More on RKTO.
- Rocket One Inc. summary
- Rocket One Inc. financial statements
- Rocket One Inc. key metrics
- Rocket One Inc. health scores and style box
- Rocket One Inc. earnings
- Rocket One Inc. dividends
- Rocket One Inc. valuation
- Rocket One Inc. ownership and insiders
- Rocket One Inc. peers
Figures from Rocket One Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.